Transmission Blocking Activity of Low-dose Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciac503 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Rebecca Webster und 16 weiteren Autor:innen. Beteiligte Einrichtung: QIMR Berghofer Medical Research Institute, Brisbane, Australia. Hauptthemen laut MEDLINE: Antimalarials, Malaria, Falciparum, Malaria, Anopheles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: QIMR Berghofer Medical Research Institute, Bill and Melinda Gates Foundation, Medicines for Malaria Venture.
Abstract (Originalsprache)
Background
Blocking the transmission of parasites from humans to mosquitoes is a key component of malaria control. Tafenoquine exhibits activity against all stages of the malaria parasite and may have utility as a transmission blocking agent. We aimed to characterize the transmission blocking activity of low-dose tafenoquine.
Methods
Healthy adults were inoculated with Plasmodium falciparum 3D7-infected erythrocytes on day 0. Piperaquine was administered on days 9 and 11 to clear asexual parasitemia while allowing gametocyte development. A single 50-mg oral dose of tafenoquine was administered on day 25. Transmission was determined by enriched membrane feeding assays predose and at 1, 4, and 7 days postdose. Artemether-lumefantrine was administered following the final assay. Outcomes were the reduction in mosquito infection and gametocytemia after tafenoquine and safety parameters.
Results
Six participants were enrolled, and all were infective to mosquitoes before tafenoquine, with a median 86% (range, 22–98) of mosquitoes positive for oocysts and 57% (range, 4–92) positive for sporozoites. By day 4 after tafenoquine, the oocyst and sporozoite positivity rate had reduced by a median 35% (interquartile range [IQR]: 16–46) and 52% (IQR: 40–62), respectively, and by day 7, 81% (IQR 36–92) and 77% (IQR 52–98), respectively. The decline in gametocyte density after tafenoquine was not significant. No significant participant safety concerns were identified.
Conclusions
Low-dose tafenoquine (50 mg) reduces P. falciparum transmission to mosquitoes, with a delay in effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- QIMR Berghofer Medical Research Institute, Brisbane, Australia.
- The University of Queensland, Brisbane, Australia.
- Australian Defence Force Malaria and Infectious Disease Institute, Brisbane, Australia.
- The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
ORCID-Profile: Bridget E Barber
Förderung
- QIMR Berghofer Medical Research Institute
- Bill and Melinda Gates Foundation
- Medicines for Malaria Venture
Zitieren
APA
Webster, R., Mitchell, H., Peters, J. M., Heunis, J., O'Neill, B., Gower, J., Lynch, S., Jennings, H., Amante, F. H., Llewellyn, S., Marquart, L., Potter, A. J., Birrell, G. W., Edstein, M. D., Shanks, G. D., McCarthy, J. S., & Barber, B. E. (2023). Transmission Blocking Activity of Low-dose Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac503
Vancouver
Webster R, Mitchell H, Peters JM, Heunis J, O'Neill B, Gower J, et al. Transmission Blocking Activity of Low-dose Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac503
BibTeX
@article{Webster2023,
author = {Webster, Rebecca and Mitchell, Hayley and Peters, Jenny M and Heunis, Juanita and O'Neill, Brighid and Gower, Jeremy and Lynch, Sean and Jennings, Helen and Amante, Fiona H and Llewellyn, Stacey and Marquart, Louise and Potter, Adam J and Birrell, Geoffrey W and Edstein, Michael D and Shanks, G Dennis and McCarthy, James S and Barber, Bridget E},
title = {Transmission Blocking Activity of Low-dose Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciac503}
}
EUVIMED